image of Clinical Handbook of Psychotropic Drugs

Clinical Handbook of Psychotropic Drugs

Publication Year:
2021
Edition:
24th Ed.
Author:
Procyshyn, Ric M.; Bezchlibnyk-Butler, Kalyna Z.
Publisher:
Hogrefe Publishing GmbH
ISBN:
978-0-88-937593-2
Print/PDF
Request Information
  • Description
  • Details
  • Collections
  • Also Recommended
Description
The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals.
  • Independent, unbiased, up-to-date
  • Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions…) for a quick overview of treatment options
  • Succinct, bulleted information on all classes of medication: on- and off-label indications, (US FDA, Health Canada), recommended dosages, US and Canadian trade names, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more – all you need to know for each class of drug
  • Potential interactions and side effects summarized in comparison charts
  • With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek
  • Clearly written patient information sheets available for download as printable PDF files
  • This book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs.

    New in this edition

    • Neuroscience-based nomenclature – added to product availability tables
    • Antidepressants chapter includes new section on GABAA receptor positive modulator (brexanolone IV injection; trade name Zulresso)
    • Also covers Qelbree (viloxazine extended-release capsules), the first new ADHD medication approved by the FDA in over a decade; as well as updates to SSRI use in pregnancy and antidepressant augmentation strategies
    • Antipsychotics updates include revised dosing, especially adjustments in hepatic and renal impairment
    • Mood stabilisers chapter sections on lithium and anticonvulsants extensively revised
    • New formulations and trade names include: Adhansia XR (methylphenidate extended-release capsules), Caplyta(lumateperone), Dayvigo (lemborexant), Perseris (risperidone extended-release subcutaneous injection), Probuphine (buprenorphine subdermal implant), Propecia (finasteride tablets), Trelstar (triptorelin slow-release injection), Qelbree (viloxazine extended-release capsules)
    Details
    Platform:
    OvidSP
    Publisher:
    Hogrefe Publishing GmbH
    Product Type:
    Book
    Author:
    Procyshyn, Ric M.; Bezchlibnyk-Butler, Kalyna Z.
    ISBN:
    978-0-88-937593-2
    Specialty:
    • Psychiatry
    • Psychology
    Language:
    English
    Edition:
    24th Ed.
    Pages:
    0
    Publication Year:
    2021

    Request Information